Literature DB >> 25744072

Intrasellar ependymoma: clinical, imaging, pathological, and surgical findings.

Jonathan M Parish1, Jose M Bonnin2, Julius M Goodman3, Aaron A Cohen-Gadol4.   

Abstract

Ependymomas arising in the intrasellar compartment are extremely rare and most often are not included in the differential diagnosis of an intrasellar tumor mass. We review the literature to further advance awareness regarding unusual presentations of this type of tumor and present an illustrative case of an intrasellar cystic ependymoma that developed in an uncommon location. In our illustrative case, the patient had a 2 year history of hypopituitarism, but no headaches or visual disturbance. Preoperatively, the lesion was thought to be a pituitary macroadenoma.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Ependymoma; Intrasellar; Pituitary fossa; Transsphenoidal surgery

Mesh:

Year:  2015        PMID: 25744072     DOI: 10.1016/j.jocn.2014.10.026

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  4 in total

Review 1.  Insights into molecular therapy of glioma: current challenges and next generation blueprint.

Authors:  Y Rajesh; Ipsita Pal; Payel Banik; Sandipan Chakraborty; Sachin A Borkar; Goutam Dey; Ahona Mukherjee; Mahitosh Mandal
Journal:  Acta Pharmacol Sin       Date:  2017-03-20       Impact factor: 6.150

Review 2.  Primary tumors of the posterior pituitary: A systematic review.

Authors:  Fernando Guerrero-Pérez; Agustina Pia Marengo; Noemi Vidal; Pedro Iglesias; Carles Villabona
Journal:  Rev Endocr Metab Disord       Date:  2019-06       Impact factor: 6.514

3.  Novel management of glioma by molecular therapies, a review article.

Authors:  Amin Alinezhad; Fatemeh Jafari
Journal:  Eur J Transl Myol       Date:  2019-08-21

Review 4.  Case Report: Sellar Ependymomas: A Clinic-Pathological Study and Literature Review.

Authors:  Liyan Zhao; Yining Jiang; Yubo Wang; Yang Bai; Liping Liu; Yunqian Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-08       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.